YU41338B - Process for obtaining cycloalkyl triazoles - Google Patents

Process for obtaining cycloalkyl triazoles

Info

Publication number
YU41338B
YU41338B YU862/79A YU86279A YU41338B YU 41338 B YU41338 B YU 41338B YU 862/79 A YU862/79 A YU 862/79A YU 86279 A YU86279 A YU 86279A YU 41338 B YU41338 B YU 41338B
Authority
YU
Yugoslavia
Prior art keywords
triazoles
cycloalkyl
obtaining
obtaining cycloalkyl
cycloalkyl triazoles
Prior art date
Application number
YU862/79A
Other languages
English (en)
Other versions
YU86279A (en
Inventor
B Silvestrini
L Baiocchi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Priority to SI7910862A priority Critical patent/SI7910862A8/sl
Publication of YU86279A publication Critical patent/YU86279A/xx
Publication of YU41338B publication Critical patent/YU41338B/xx
Priority to HR940112A priority patent/HRP940112B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YU862/79A 1978-04-18 1979-04-11 Process for obtaining cycloalkyl triazoles YU41338B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI7910862A SI7910862A8 (sl) 1978-04-18 1979-04-11 Postopek za pridobivanje cikloalkil-triazola
HR940112A HRP940112B1 (en) 1978-04-18 1994-02-15 Process for the preparation of cycloalkyl triazoles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT22421/78A IT1094076B (it) 1978-04-18 1978-04-18 Cicloalchiltriazoli

Publications (2)

Publication Number Publication Date
YU86279A YU86279A (en) 1983-12-31
YU41338B true YU41338B (en) 1987-02-28

Family

ID=11196066

Family Applications (1)

Application Number Title Priority Date Filing Date
YU862/79A YU41338B (en) 1978-04-18 1979-04-11 Process for obtaining cycloalkyl triazoles

Country Status (22)

Country Link
US (2) US4252721A (da)
JP (1) JPS5817757B2 (da)
AT (1) AT374477B (da)
AU (1) AU520788B2 (da)
BG (2) BG40654A3 (da)
CA (1) CA1104567A (da)
CH (1) CH639847A5 (da)
DE (1) DE2915318A1 (da)
DK (1) DK148480C (da)
FI (1) FI66378C (da)
FR (1) FR2423221A1 (da)
GB (1) GB2020269B (da)
HU (1) HU179917B (da)
IE (1) IE47965B1 (da)
IL (1) IL56926A (da)
IT (1) IT1094076B (da)
NL (1) NL186635C (da)
PL (1) PL116103B1 (da)
PT (1) PT69502A (da)
SE (1) SE437663B (da)
SU (1) SU852174A3 (da)
YU (1) YU41338B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
US4879294A (en) * 1988-01-28 1989-11-07 Angelini Pharmaceuticals Ltd. Opthalmic composition
IT1224250B (it) * 1988-06-10 1990-09-26 Acraf Associzione del depiprazolo con la morfina
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
US5288759A (en) * 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US6187774B1 (en) 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
EP1891954A3 (en) 1998-09-30 2009-01-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
EP1410808A4 (en) * 2001-07-02 2009-07-29 Santen Pharmaceutical Co Ltd MEDIUM FOR THE PROTECTION OF THE SEHNERV WITH ALPHA 1 RECEPTOR BLOCKER AS AN ACTIVE SUBSTANCE
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20030229001A1 (en) * 2002-01-31 2003-12-11 Pfizer Inc. Treatment of male sexual dysfunction
CN1681495B (zh) 2002-08-19 2010-05-12 辉瑞产品公司 用于治疗过度增生性疾病的组合物
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) * 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004106299A2 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives and their use as hmg-co inhibitors
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
US20050288270A1 (en) * 2004-05-27 2005-12-29 Pfizer Inc New aminopyridine derivatives and their use as pharmaceuticals
JP2008533192A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
JP2008533193A (ja) * 2005-03-21 2008-08-21 ファイザー・リミテッド オキシトシン拮抗薬としての置換トリアゾール誘導体
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3870170A4 (en) 2018-10-26 2022-07-20 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
CN113574055A (zh) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913454A (en) * 1956-11-23 1959-11-17 Schenley Ind Inc Certain cycloalkanotriazoles, process and intermediates
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3472853A (en) * 1967-05-29 1969-10-14 Sterling Drug Inc 1-((pyrido(2,1-c)-s-triazolyl)-lower-alkyl)-4-substituted- piperazines
JPS5070389A (da) * 1973-10-30 1975-06-11

Also Published As

Publication number Publication date
DE2915318A1 (de) 1979-10-31
PT69502A (en) 1979-05-01
DK148480B (da) 1985-07-15
FI66378B (fi) 1984-06-29
NL186635C (nl) 1991-01-16
FR2423221B1 (da) 1983-03-18
FR2423221A1 (fr) 1979-11-16
GB2020269B (en) 1982-06-03
CA1104567A (en) 1981-07-07
FI66378C (fi) 1984-10-10
US4307095A (en) 1981-12-22
DE2915318C2 (da) 1990-12-13
ATA292479A (de) 1983-09-15
AU4583279A (en) 1979-10-25
NL186635B (nl) 1990-08-16
CH639847A5 (it) 1983-12-15
FI791217A (fi) 1979-10-19
IL56926A (en) 1983-09-30
IT1094076B (it) 1985-07-26
PL116103B1 (en) 1981-05-30
JPS5817757B2 (ja) 1983-04-09
DK156779A (da) 1979-10-19
SU852174A3 (ru) 1981-07-30
PL214969A1 (da) 1980-03-10
HU179917B (en) 1983-01-28
JPS54157576A (en) 1979-12-12
SE437663B (sv) 1985-03-11
IL56926A0 (en) 1979-05-31
IE47965B1 (en) 1984-08-08
IE790646L (en) 1979-10-18
AT374477B (de) 1984-04-25
NL7902489A (nl) 1979-10-22
SE7903327L (sv) 1979-10-19
BG61367B2 (bg) 1997-06-30
DK148480C (da) 1985-12-16
US4252721A (en) 1981-02-24
BG40654A3 (en) 1987-01-15
GB2020269A (en) 1979-11-14
YU86279A (en) 1983-12-31
AU520788B2 (en) 1982-02-25
IT7822421A0 (it) 1978-04-18

Similar Documents

Publication Publication Date Title
YU41338B (en) Process for obtaining cycloalkyl triazoles
PT69685A (en) Process for preparing herbicids containing pirazolic etherderivatives
YU170479A (en) Process for preparing 2-chloro-6-nitroanilines
YU93179A (en) Process for obtaining 4-deacetyl-vinca-leublastin c-3-carboxhydrazide
GB2018816B (en) Process for preparing hexamethyltetrahydronaphthalenes
PH19618A (en) Process for preparing -2-pyrrolidone
YU241279A (en) Process for obtaining 2-chlorosulfinyl-azetidine-4-one
YU227679A (en) Process for obtaining n-benzylhaloacetamide deriatives
GB2019835B (en) Process for preparing n-carbamoyl-d-thienylglycines
YU67679A (en) Process for obtaining dilignol like compounds
YU112279A (en) Process for obtaining substituted dibenzylethers
YU86879A (en) Process for obtaining 17-beta-carboxy-5-androstane-3-one
DE2960047D1 (en) Process for preparing 2-oximinophenylacetonitrile
DE2961058D1 (en) Process for preparing alpha-chloro-n-monoalkyl-acetoacetamides
JPS5548324A (en) Sprouting process for regular shimejiimushroom
YU41093B (en) Process for preparing 6-deoxy-5hydroxy-tetracycline
GB2018783B (en) Process for preparing polyolefins
YU304478A (en) Process for obtaining chloro-acetanilides
YU40533B (en) Process for preparing 2-bromoergosinine
YU134179A (en) Process for obtaining n-phenethylimidazole deivatives
DE2964629D1 (en) Process for preparing 3-amino-5-t-butylisoxazole
HRP940112B1 (en) Process for the preparation of cycloalkyl triazoles
YU41345B (en) Process for obtaining chloroambucial
YU169879A (en) Process for obtaining cis-bicyclooctyl-amine
DE2963897D1 (en) Process for preparing sodium-m-nitrobenzenesulfonate